PsO in the genital area and its consequences on sexual health are highly relevant topics and a huge burden of disease for the affected patients. Data on the prevalence of genital PsO and its relation to sexual impairment in the German setting as well as the potential effectiveness of Risankizumab in treating genital PsO is missing. Therefore, the study aims to answer the following research question:
How effective is a therapy with Risankizumab to improve genital psoriasis and sexual impairment in a prospective real-life setting? – PART B, prospective observational non-interventional study